Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells
Purpose: Patients with MYC-amplified Group 3 medulloblastoma (MB) (subtype II) show poor progression-free survival rates. Class I histone deacetylase inhibitors (HDACi) are highly effective for the treatment of MYC-amplified MB in vitro and in vivo. Drug combination regimens including class I HDACi...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
07 January 2024
|
| In: |
Journal of neuro-oncology
Year: 2024, Jahrgang: 166, Pages: 99-112 |
| ISSN: | 1573-7373 |
| DOI: | 10.1007/s11060-023-04526-w |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s11060-023-04526-w
|
| Verfasserangaben: | Simon Zeuner, Johanna Vollmer, Romain Sigaud, Sina Oppermann, Heike Peterziel, Dina ElHarouni, Ina Oehme, Olaf Witt, Till Milde, Jonas Ecker |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1884376304 | ||
| 003 | DE-627 | ||
| 005 | 20250327140036.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240326s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11060-023-04526-w |2 doi | |
| 035 | |a (DE-627)1884376304 | ||
| 035 | |a (DE-599)KXP1884376304 | ||
| 035 | |a (OCoLC)1443667877 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Zeuner, Simon |e VerfasserIn |0 (DE-588)1324494689 |0 (DE-627)188437672X |4 aut | |
| 245 | 1 | 0 | |a Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells |c Simon Zeuner, Johanna Vollmer, Romain Sigaud, Sina Oppermann, Heike Peterziel, Dina ElHarouni, Ina Oehme, Olaf Witt, Till Milde, Jonas Ecker |
| 264 | 1 | |c 07 January 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.03.2024 | ||
| 520 | |a Purpose: Patients with MYC-amplified Group 3 medulloblastoma (MB) (subtype II) show poor progression-free survival rates. Class I histone deacetylase inhibitors (HDACi) are highly effective for the treatment of MYC-amplified MB in vitro and in vivo. Drug combination regimens including class I HDACi may represent an urgently needed novel treatment approach for this high risk disease. Methods: A medium-throughput in vitro combination drug screen was performed in three MYC-amplified and one non-MYC-amplified MB cell line testing 75 clinically relevant drugs alone and in combination with entinostat. The drug sensitivity score (DSS) was calculated based on metabolic inhibition quantified by CellTiter-Glo. The six top synergistic combination hits were evaluated in a 5 × 5 combination matrix and a seven-ray design. Synergy was validated and characterized by cell counts, caspase-3-like-activity and poly-(ADP-ribose)-polymerase-(PARP)-cleavage. On-target activity of drugs was validated by immunoprecipitation and western blot. BCL-XL dependency of the observed effect was explored with siRNA mediated knockdown of BCL2L1, and selective inhibition with targeted compounds (A-1331852, A-1155463). Results: 20/75 drugs effectively reduced metabolic activity in combination with entinostat in all three MYC-amplified cell lines (DSS ≥ 10). The combination entinostat and navitoclax showed the strongest synergistic interaction across all MYC-amplified cell lines. siRNA mediated knockdown of BCL2L1, as well as targeted inhibition with selective inhibitors showed BCL-XL dependency of the observed effect. Increased cell death was associated with increased caspase-3-like-activity. Conclusion: Our study identifies the combination of class I HDACi and BCL-XL inhibitors as a potential new approach for the treatment of MYC-amplified MB cells. | ||
| 650 | 4 | |a BCL-XL | |
| 650 | 4 | |a Drug screen | |
| 650 | 4 | |a HDAC | |
| 650 | 4 | |a Medulloblastoma | |
| 650 | 4 | |a MYC | |
| 700 | 1 | |a Vollmer, Johanna |e VerfasserIn |0 (DE-588)1315043955 |0 (DE-627)1877275212 |4 aut | |
| 700 | 1 | |a Sigaud, Romain |e VerfasserIn |4 aut | |
| 700 | 1 | |a Oppermann, Sina |d 1986- |e VerfasserIn |0 (DE-588)1052898602 |0 (DE-627)789270862 |0 (DE-576)408636513 |4 aut | |
| 700 | 1 | |a Peterziel, Heike |e VerfasserIn |0 (DE-588)1079032606 |0 (DE-627)840098022 |0 (DE-576)452152348 |4 aut | |
| 700 | 1 | |a ElHarouni, Dina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Oehme, Ina |d 1974- |e VerfasserIn |0 (DE-588)129573388 |0 (DE-627)473352621 |0 (DE-576)297728652 |4 aut | |
| 700 | 1 | |a Witt, Olaf |d 1965- |e VerfasserIn |0 (DE-588)17275030X |0 (DE-627)697681750 |0 (DE-576)133607410 |4 aut | |
| 700 | 1 | |a Milde, Till |d 1973- |e VerfasserIn |0 (DE-588)1038311837 |0 (DE-627)75711234X |0 (DE-576)39229334X |4 aut | |
| 700 | 1 | |a Ecker, Jonas |d 1988- |e VerfasserIn |0 (DE-588)109722810X |0 (DE-627)857006886 |0 (DE-576)468135251 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neuro-oncology |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1983 |g 166(2024), Seite 99-112 |h Online-Ressource |w (DE-627)32046122X |w (DE-600)2007293-4 |w (DE-576)107058944 |x 1573-7373 |7 nnas |a Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells |
| 773 | 1 | 8 | |g volume:166 |g year:2024 |g pages:99-112 |g extent:14 |a Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells |
| 787 | 0 | 8 | |i Errata |a Kocheise, Lorenz, 1994 - |t Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease |d 2024 |w (DE-627)1884394795 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s11060-023-04526-w |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240326 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 109722810X |a Ecker, Jonas |m 109722810X:Ecker, Jonas |d 910000 |d 910500 |e 910000PE109722810X |e 910500PE109722810X |k 0/910000/ |k 1/910000/910500/ |p 10 |y j | ||
| 998 | |g 1038311837 |a Milde, Till |m 1038311837:Milde, Till |d 910000 |d 910500 |d 50000 |e 910000PM1038311837 |e 910500PM1038311837 |e 50000PM1038311837 |k 0/910000/ |k 1/910000/910500/ |k 0/50000/ |p 9 | ||
| 998 | |g 17275030X |a Witt, Olaf |m 17275030X:Witt, Olaf |d 910000 |d 910500 |e 910000PW17275030X |e 910500PW17275030X |k 0/910000/ |k 1/910000/910500/ |p 8 | ||
| 998 | |g 129573388 |a Oehme, Ina |m 129573388:Oehme, Ina |d 50000 |e 50000PO129573388 |k 0/50000/ |p 7 | ||
| 998 | |g 1079032606 |a Peterziel, Heike |m 1079032606:Peterziel, Heike |d 50000 |e 50000PP1079032606 |k 0/50000/ |p 5 | ||
| 998 | |g 1052898602 |a Oppermann, Sina |m 1052898602:Oppermann, Sina |d 50000 |e 50000PO1052898602 |k 0/50000/ |p 4 | ||
| 998 | |g 1315043955 |a Vollmer, Johanna |m 1315043955:Vollmer, Johanna |d 910000 |d 910500 |e 910000PV1315043955 |e 910500PV1315043955 |k 0/910000/ |k 1/910000/910500/ |p 2 | ||
| 998 | |g 1324494689 |a Zeuner, Simon |m 1324494689:Zeuner, Simon |d 910000 |d 910500 |e 910000PZ1324494689 |e 910500PZ1324494689 |k 0/910000/ |k 1/910000/910500/ |p 1 |x j | ||
| 999 | |a KXP-PPN1884376304 |e 4504067331 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells","title":"Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells"}],"physDesc":[{"noteIll":"Illustrationen","extent":"14 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Journal of neuro-oncology","title":"Journal of neuro-oncology"}],"part":{"volume":"166","text":"166(2024), Seite 99-112","pages":"99-112","year":"2024","extent":"14"},"pubHistory":["1.1983 -"],"note":["Gesehen am 11.06.2018","Fortsetzung der Druck-Ausgabe"],"language":["eng"],"disp":"Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cellsJournal of neuro-oncology","origin":[{"dateIssuedKey":"1983","publisherPlace":"Dordrecht [u.a.] ; Dordrecht [u.a.]","dateIssuedDisp":"1983-","publisher":"Springer Science + Business Media B.V ; Kluwer"}],"id":{"issn":["1573-7373"],"eki":["32046122X"],"zdb":["2007293-4"]},"recId":"32046122X","type":{"bibl":"periodical","media":"Online-Ressource"}}],"person":[{"family":"Zeuner","role":"aut","display":"Zeuner, Simon","given":"Simon"},{"family":"Vollmer","role":"aut","display":"Vollmer, Johanna","given":"Johanna"},{"given":"Romain","family":"Sigaud","role":"aut","display":"Sigaud, Romain"},{"given":"Sina","display":"Oppermann, Sina","family":"Oppermann","role":"aut"},{"given":"Heike","display":"Peterziel, Heike","role":"aut","family":"Peterziel"},{"given":"Dina","display":"ElHarouni, Dina","family":"ElHarouni","role":"aut"},{"display":"Oehme, Ina","family":"Oehme","role":"aut","given":"Ina"},{"given":"Olaf","family":"Witt","role":"aut","display":"Witt, Olaf"},{"role":"aut","family":"Milde","display":"Milde, Till","given":"Till"},{"display":"Ecker, Jonas","role":"aut","family":"Ecker","given":"Jonas"}],"language":["eng"],"note":["Gesehen am 26.03.2024"],"name":{"displayForm":["Simon Zeuner, Johanna Vollmer, Romain Sigaud, Sina Oppermann, Heike Peterziel, Dina ElHarouni, Ina Oehme, Olaf Witt, Till Milde, Jonas Ecker"]},"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"07 January 2024"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.1007/s11060-023-04526-w"],"eki":["1884376304"]},"recId":"1884376304"} | ||
| SRT | |a ZEUNERSIMOCOMBINATIO0720 | ||